Genesis Therapeutics
- Headquarters
- Burlingame
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- genesistherapeutics.ai
- Total Funding
- $256.1M
- Last Round
- $200.0M Series BAug 2023
About
Genesis Therapeutics uses its proprietary GEMS platform, combining deep learning and molecular simulations, to discover small molecule drugs for challenging disease targets. Backed by over $300M from Andreessen Horowitz, NVIDIA, and Fidelity, the company has established major platform collaborations with Gilead, Genentech, and Incyte.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account